Long Position on HRMY @ $40.50 on 12/21/2021 (Fundamentals)

Harmony Biosciences Holdings, Inc. (HRMY), a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders.

Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States.

The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.

Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc. reported 3rd Quarter September 2021 earnings of $0.43 per share on revenue of $80.7 million. The consensus earnings estimate was $0.19 per share on revenue of $80.9 million. Revenue grew 77.0% on a year-over-year basis.

After being added to the NASDAQ earlier this month, the stock should see an increase along its "trendline support". 

Entry Point: $40.50

Stop Loss: $38.50

Trading Range: $25.09 - $44.39

Target Price: $44.55

Position closed on 2/1/2022 at price of $37.50 with a -7.41% loss in 42 days.

Back to Portfolio